August 03, 2016
Weil’s Antitrust team advised Allergan plc, a leading global pharmaceutical company, in the recently completed divestiture of its global generic pharmaceuticals business to Teva Pharmaceutical Industries Ltd, a transaction valued at approximately $39 billion.
Weil has advised Allergan in numerous other prominent Antitrust matters including:
- Allergan’s approximately $160 billion merger agreement with Pfizer Inc. (November 23, 2015)
- Allergan’s approximately $2.1 billion acquisition of KYTHERA Biopharmaceuticals Inc. (June 18, 2015)
- Actavis plc’s approximately $70.5 billion acquisition of Allergan (November 17, 2014)